Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Jonsson

Showing results (21-30 of 54) with videos related to

Pageof 6
Sort By:
Breast Cancer Research : BCR|July 2, 2013
Liver × receptor ligands disrupt breast cancer cell proliferation through an E2F-mediated mechanismTrang Nguyen-Vu, Lise-Lotte Vedin, Ka Liu, et al.
The Journal of Clinical Endocrinology and Metabolism|August 8, 2018
Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and NivolumabAndrew L Lin, Philip Jonsson, Viviane Tabar, et al.
Cancer Discovery|June 9, 2018
A Secondary Mutation in <i>BRAF</i> Confers Resistance to RAF Inhibition in a <i>BRAF</i><sup>V600E</sup>-Mutant Brain TumorJiawan Wang, Zhan Yao, Philip Jonsson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2020
A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung CancersPaul K Paik, Rachel K Kim, Linda Ahn, et al.
Cell Stem Cell|August 15, 2017
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical OutcomesCatherine C Coombs, Ahmet Zehir, Sean M Devlin, et al.
Autophagy|December 16, 2016
Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progressionAlicia M Blessing, Kimal Rajapakshe, Lakshmi Reddy Bollu, et al.
Cancer Discovery|August 25, 2023
STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant XenograftsLeonard Buckbinder, David J St Jean, Trang Tieu, et al.
Journal of Medicinal Chemistry|January 17, 2025
Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung CancerBenjamin C Milgram, Deanna R Borrelli, Natasja Brooijmans, et al.
JCO Precision Oncology|December 7, 2020
Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway GenesEvan Rosenbaum, Philip Jonsson, Kenneth Seier, et al.
Nature|May 29, 2020
Phase and context shape the function of composite oncogenic mutationsAlexander N Gorelick, Francisco J Sánchez-Rivera, Yanyan Cai, et al.
Pageof 6

Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
Breast Cancer Research : BCR|July 2, 2013
Liver × receptor ligands disrupt breast cancer cell proliferation through an E2F-mediated mechanismTrang Nguyen-Vu, Lise-Lotte Vedin, Ka Liu, et al.
The Journal of Clinical Endocrinology and Metabolism|August 8, 2018
Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and NivolumabAndrew L Lin, Philip Jonsson, Viviane Tabar, et al.
Cancer Discovery|June 9, 2018
A Secondary Mutation in <i>BRAF</i> Confers Resistance to RAF Inhibition in a <i>BRAF</i><sup>V600E</sup>-Mutant Brain TumorJiawan Wang, Zhan Yao, Philip Jonsson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2020
A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung CancersPaul K Paik, Rachel K Kim, Linda Ahn, et al.
Cell Stem Cell|August 15, 2017
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical OutcomesCatherine C Coombs, Ahmet Zehir, Sean M Devlin, et al.
Autophagy|December 16, 2016
Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progressionAlicia M Blessing, Kimal Rajapakshe, Lakshmi Reddy Bollu, et al.
Cancer Discovery|August 25, 2023
STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant XenograftsLeonard Buckbinder, David J St Jean, Trang Tieu, et al.
Journal of Medicinal Chemistry|January 17, 2025
Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung CancerBenjamin C Milgram, Deanna R Borrelli, Natasja Brooijmans, et al.
JCO Precision Oncology|December 7, 2020
Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway GenesEvan Rosenbaum, Philip Jonsson, Kenneth Seier, et al.
Nature|May 29, 2020
Phase and context shape the function of composite oncogenic mutationsAlexander N Gorelick, Francisco J Sánchez-Rivera, Yanyan Cai, et al.
Pageof 6